Alnylam stock jumps 15% after a surprise Q2 profit, driven by soaring Amvuttra sales and raised 2025 revenue guidance.

Polyneuropathy is one of the most common complications in people with diabetes. However, it can also occur with certain risk factors or diseases before the onset of diabetes.

The Food and Drug Administration (FDA) has approved Amvuttra ™ (vutrisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated (hATTR) amyloidosis in adults ...

The FDA has granted regulatory approval for WAINUA for the treatment of polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults, according to a press release. Wainua (eplontersen ...

BOSTON — In a small study of patients labeled as having fibromyalgia, almost half actually had small-fiber polyneuropathy (SFPN), a potentially treatable condition. Therefore, it is important ...

Wainua™ (eplontersen) granted regulatory approval in the US for the treatment of adults with polyneuropathy of hereditary transthyretin-mediated amyloidosis. News release. Ionis Pharmaceuticals.

In addition to 'Polyneuropathy', there may be other similar symptoms or signs that better match your side effect. These have also been listed below for your convenience. If you find a symptom that ...

Polyneuropathy plus pain was a predictor of number of vascular events, with an incidence rate ratio (IRR) of 1.55 (95% CI, 1.29-1.85) compared with no polyneuropathy.

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that the HELIOS-A Phase 3 study of vutrisiran, an ...

Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) announced today that Ionis' and AstraZeneca's WAINZUA (eplontersen) has been recommended for approval by the Committee for Medicinal Products for Human ...

ICU-acquired weakness, with documented polyneuropathy, myopathy, or both, can be subclassified. Critical illness polyneuropathy refers to ICU-acquired weakness with electrophysiological evidence ...